Back to search
Biochemically Recurrent Prostate Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Biochemically Recurrent Prostate Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Biochemically Recurrent Prostate Cancer trials you may qualify forBackground: Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their e…
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination wi…
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI…
TerbinaPro is a phase II drug-repurposing study evaluating oral Terbinafine in patients with biochemical recurrence of prostate cancer after prior local treatme…
This phase II trial evaluates the impact of cancer therapy in the patients' home compared to in the clinic on safety, side effects, patient preference, and sati…
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with p…
This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab
Main Study: The purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk local…
In this observational study, participants receive darolutamide: a treatment that is already available for doctors to prescribe for non-metastatic castration-res…